Materials and Methods: The data of patients treated for bladder tumors in two tertiary centers between December 2018 and December 2024 were analyzed retrospectively. Patients who were younger than 18 years of age at the time of diagnosis and whose pathology was reported as UC were included in the study. Transurethral resection of the bladder tumors was carried out on all patients. Age, gender, presentation symptoms, tobacco use or exposure, imaging method, number of tumors, tumor size, histological findings, hospitalization time, complications, tumor recurrence, and follow-up data were examined.
Results: Four female and three male patients were included in the study. The mean age of the patients was 14.8 ± 2.1 (12–17) years. The most common symptom was hematuria. Mean tumor size was 20.5 ± 9.8 (14–40) mm, and all were low-grade. No recurrence was detected at a mean of 58 ± 13.8 (44–76) months after resection.
Conclusion: Urothelial carcinoma of the bladder is rare in the pediatric population. These neoplasms are usually low grade, and recurrence is rare. The most common recurrences are seen in the first year. Strict follow-up is essential in this period. Less invasive tools can be used for follow-up after the first year on low-grade neoplasms.
The most common symptom at the time of diagnosis is hematuria. Dysuria, suprapubic pain, frequency, and obstructive symptoms are other less common symptoms [1]. Bladder tumors in the pediatric population are commonly detected by urinary system ultrasound (USG) [1,3]. A cystoscopy should be performed under general anesthesia for definitive diagnosis and treatment if a bladder tumor is suspected due to the patient's medical history and radiological imaging [4].
Urothelial carcinomas usually tend to be low grade and present a lower incidence of invasiveness in children and adolescents [2,5]. According to a World Health Organization (WHO) classification in 2004, approximately 3% of pediatric cases are high-grade diseases, while most cases are papillary urothelial neoplasms of low malignant potential (PUNLMP) [1,6]. Therefore, the incidence and recurrence rates of invasive tumors diverge from those of adults. There is also a higher disease-free survival rate in pediatric cases [2,7,8]. The recurrence rate ranges from 8% to 15%, and more than twothirds of recurrences occur in the first year [1,3,4,8].
Urothelial carcinomas are rare in the pediatric population, so standardized recommendations have not been clearly defined for their management. Although some authors state that the adult follow-up protocol may be preferred, uncertainty remains in the management of pediatric bladder UC, which differs significantly from adults in terms of clinical, histological, and prognosis [3,4]. In this study, we report our experience and long-term followup data with low-grade urothelial bladder neoplasms in pediatric patients.
Urinary ultrasounds were used as the first imaging method before treatment in all patients. A computed tomography was applied in two patients with tumor sizes of 25 mm and 40 mm and in one patient with a hematoma in the bladder.
Age, gender, presentation symptoms, tobacco use or exposure, number of tumors, tumor size, histological findings, hospitalization time, complications, tumor recurrence, and follow-up data were examined.
Surgery and Follow-up
The patients were prepared for a cystoscopy, which was
performed under general anesthesia in the lithotomy position.
Cystoscopies were performed using a 9.5 Fr 13 cm pediatric
cystoscope in two prepubertal patients and a 17 Fr rigid
cystoscope in five adolescent patients with an appropriate
urethral caliber. The transurethral resection of bladder tumors
(TURB) was conducted using a 9 Fr 12 cm monopolar pediatric
resectoscope in two prepubertal patients and a 24 Fr bipolar
resectoscope in five adolescent patients with an appropriate
urethral caliber.
After resection, a 10 Fr Foley catheter was inserted in two prepubertal patients, and an 18 Fr three-way Foley catheter was inserted in five adolescent patients. In patients without macroscopic hematurias, the catheter was removed on the first to third postoperative days, and the patients were discharged. In the second postoperative week, the patients were called for a pathology.
For recurrence control, a urinanalysis, urinary USG, and cystoscopy were performed postoperatively at the third, sixth, and 12th months. Subsequently, urinanalyses and ultrasounds were performed every six months.
Statistical Analysis
The SPSS, v.23.0 statistical software (SPSS, Inc., Chicago,
IL, USA) package program was utilized for statistical analysis.
Descriptive statistical analyses were assessed by mean, standard
deviation, and minimum and maximum values. Hospitalization
time was expressed as the median value due to the standard
deviation.
Ethics and Consent to Participate
All procedures performed in this study involving human
participants were conducted in accordance with the ethical
standards of the institutional and/or national research committee
and with the 1964 Helsinki declaration and its later amendments
or comparable ethical standards. Consent, according to the
Helsinki Declaration, was taken from the Necmettin Erbakan
University Faculty of Medicine Ethics Committee before the
study (No: 2022/3711). Consent to participate was obtained
from all parents before the study.
Table 1. Patients demographic and clinical data
Table 2: Descriptive statistical analyses of the patients
Figure 1. Patients preoperative computed tomography images
While six (85.7%) patients had solitary papillary tumors, one patient with a total tumor diameter of 40 mm had three papillary tumors. The mean tumor size was 20.5 ± 9.8 (14–40) mm. According to the WHO classification (2004), papillomas were detected in two (28.6%) patients, PUNLMP in three (42.8%) patients, and non-invasive low-grade UC in two (28.6%) patients (Table 1,2).
Patients were discharged on a median of 3 (2–3) days without complications. Intracavitary instillations were not performed on any patients. No recurrence was detected in patients at a mean of 58 ± 13.8 (44–76) months after their resections (Table 2).
Most articles about pediatric bladder UC, including followup data in the literature, also include young adult patients. To the best of our knowledge, the largest pediatric series includes fewer than 20 patients [9]. According to the literature, approximately less than 5% of urothelial carcinomas in the pediatric group are high-grade tumors or have submucosal invasion [4,10]. In our study, most tumors were PUNLMP or low-grade UC, and no high-grade tumors were detected. Tumor genetics are thought to be the reason UCs have a benign course in the pediatric population, unlike adults. Wild et al. evaluated patients under 19 years of age. They stated that genetic changes such as FGFR 3 mutation, chromosome 9 alteration, aneuploidy, and TP53 mutation—high-grade tumors that are common in adults— are very rare in pediatric patients. Therefore, it may cause differences in tumor biology [10]. In addition, genetic changes, such as low microsatellite instability and low expression of MIB- 1, a proliferation index, have been associated with a lower grade and noninvasive course of pediatric Ucs [11,12]. The common hypothesis of different genetic studies is that pediatric UC has greater "genetic stability" than adult UC [13]. A genetically stable tumor that is less biologically aggressive may lead to less invasion and a lower-grade benign course of the disease.
Tobacco use is a well-known risk factor for adult bladder neoplasms. It facilitates tumorigenesis by causing DNA methylation in genes related to bladder tumors [14,15]. Nevertheless, in the current literature, smoking is not considered an exact risk factor for pediatric bladder tumors. However, it has been stated that the age of smoking initiation in children has been decreasing [16]. In our study, 42.8% of the patients were smokers. Smoking might also be regarded as a risk factor in the pediatric population. To reduce smoking-related health problems, such as bladder tumors, national and international policies regarding the prevention and cessation of smoking, especially in children and adolescents, should be carefully determined and followed.
The most common presenting symptom in our study, similar to the literature on pediatric UCs, is painless hematuria [1,3,4,8]. However, unlike in adults, hematuria in children rarely indicates an underlying malignancy. The most common etiological factors of hematuria in children are infection, glomerulonephritis, and hypercalciuria [17]. Although bladder tumors are a rare etiological factor, they should be considered in the differential diagnosis of recurrent hematuria in the pediatric population. Therefore, urinanalyses and urinary ultrasounds are essential tools for the diagnosis of bladder tumors in children with recurrent and/or resistant hematuria. In addition, a urine microscopy and the evaluation of red cell morphology may aid diagnoses. Isomorphic blood cells may suggest that hematuria has bladderrelated origins rather than glomerular or tubular origins. Bladder USG has a higher sensitivity in children and adolescents than adults due to its thinner abdominal fat and muscle layer [3]. In the present study, all tumors were detected with USG. Subsequently, the diagnosis was confirmed by a cystoscopy.
The transurethral resection of bladder tumors is an essential procedure for the diagnosis and treatment of bladder neoplasms [18]. A complete resection with clear negative margins and obtained muscularis propria will lead to a quality pathological evaluation and, therefore, more accurate disease management [19]. In our study, complete TURB was performed with negative margins, and muscularis propria was obtained in all patients. We did not observe complications in our patients. No residual tumors were detected in the long-term follow-up. Unlike adults, transurethral resections, especially in prepubertal patients, involve technical difficulties, such as the narrow urethral caliber and lack of drainage channels in the resectoscope. The narrow sheath of the resectoscope for the removal of resected materials is another challenging issue, especially in male patients. To overcome the drainage problem, we placed a feeding catheter into the urethra during resectioning in a prepubertal female patient.
Uncertainty related to follow-up remains [20]. The European Association of Urology (EAU) pediatric urology guidelines state that the adult follow-up protocol could be used for bladder UC follow-up in the pediatric patient group [18]. Conversely, some authors advocate that a less aggressive follow-up protocol could be applied in pediatric patients because pediatric UC has a lower recurrence rate than adults [9,21]. In addition, a cystoscopy is the gold standard for diagnosis; however, the use of a cystoscopy in follow-up is also controversial in pediatric patients [22]. It has disadvantages, such as being an invasive procedure and requiring anesthesia. Urinary cytology has high sensitivity (70%–80%) in high-grade UC, although sensitivity decreases to 6%–38% in low-grade tumors [23,24]. Because pediatric UCs on the bladder are usually low-grade tumors, cytology is far from routine [21,25]. The use of tomography in follow-ups is limited because of ionizing radiation [26]. Ultrasonography is a highly sensitive and non-invasive tool in diagnosing pediatric bladder tumors and is the most frequently used tool in follow-up [22].
In this series, we chose to perform a stricter follow-up. A cystoscopy, USG, and urinalysis were performed postoperatively at the third, sixth, and 12th months in the first year when recurrences were most commonly witnessed [22]. Since highgrade and invasive UC was not detected in our patients after the first year, we performed a urinalysis and USG every six months to protect the patients from anesthesia. We did not prefer cytology in the follow-up due to its low sensitivity. With this follow-up protocol, we did not observe recurring tumors.
The main limitation of our study was its few patients. Given the very low incidence of urothelium bladder neoplasms originating in the pediatric population, the current limitation applies to most studies in the literature. Another limitation is that patients" family history of bladder tumors is not adequately questioned. Genetic predisposition is not a definitive risk factor for pediatric UC and should be studied further. Finally, genetic changes, such as FGFR 3 mutation, chromosome 9 alteration, and TP53 mutation, which are frequently observed in bladder tumors, have not been investigated. The genetic origins of pediatric UC have not been clearly defined, and there is insufficient data in the literature on the suitability of genetic tests for clinical use. Despite these limitations, the present study comprises purely pediatric UC patients with long-term follow-up data. We are confident that the data we share on the isolated pediatric population will contribute to the management approach of very rare bladder UC.
Ethics Committee Approval: Ethical approval for this study was obtained from Necmettin Erbakan University Faculty of Medicine Ethics Committee before the study (Ethics committee approval number: 2022/3711).
Informed Consent: An informed consent was obtained from all the patients.
Publication: The results of the study were not published in full or in part in form of abstracts.
< b>Peer-review: Externally peer-reviewed.
Authorship Contributions: Any contribution was not made by any individual not listed as an author. Concept – M.T.K., A.S.; Design – M.T.K., M.M.P; Supervision – M.S.Ö., M.M.P.; Resources – M.T.K., M.S.Ö.; Materials – M.T.K., A.S., M.M.P.; Data Collection and/or Processing – M.T.K., A.S.; Analysis and/ or Interpretation – M.T.K.; Literature Search – M.T.K., M.S.Ö., M.M.P.; Writing Manuscript – M.T.K., M.S.Ö., M.M.P.; Critical Review – M.S.Ö., M.M.P.
Conflict of Interest: The authors declare that they have no conflicts of interest.
Financial Disclosure: The authors declare that this study received no financial support.
1) Chu S, Singer J. Transitional cell carcinoma in the pediatric
patient: A review of the literature. Urology 2016;91:175-9.
https://doi.org/10.1016/j.urology.2015.12.032
2) Fine SW, Humphrey PA, Dehner LP, Amin MB, Epstein
JI. Urothelial neoplasms in patients 20 years or younger:
A clinicopathological analysis using the world health
organization 2004 bladder consensus classification. J Urol
2005;174(5):1976-80.
https://doi.org/10.1097/01.ju.0000176801.16827.82
3) Caione P, Patruno G, Pagliarulo V, Bulotta AL, Salerno A,
Diomedi Camassei F, et al. Nonmuscular invasive urothelial
carcinoma of the bladder in pediatric and young adult
patients: Age-related outcomes. Urology 2017;99:215-20.
https://doi.org/10.1016/j.urology.2016.07.009
4) Saltsman JA, Malek MM, Reuter VE, Hammond WJ,
Danzer E, Herr HW, et al. Urothelial neoplasms in
pediatric and young adult patients: A large single-center
series. J Pediatr Surg 2018;53(2):306-9.
https://doi.org/10.1016/j.jpedsurg.2017.11.024
5) Compérat E, Larré S, Roupret M, Neuzillet Y, Pignot G,
Quintens H, et al. Clinicopathological characteristics of
urothelial bladder cancer in patients less than 40 years old.
Virchows Arch 2015;466(5):589-94.
https://doi.org/10.1007/s00428-015-1739-2
6) Jaworski D, Szylberg Ł, Gzil A, Stawinski P, Kasperska A,
Marszałek A. Diagnostic difficulties in cases of papillary
urothelial neoplasm of low malignant potential, urothelial
proliferation of uncertain malignant potential, urothelial
dysplasia and urothelial papilloma: A review of current
literature. Ann Diagn Pathol 2019;40:182-8.
https://doi.org/10.1016/j.anndiagpath.2017.12.007
7) Yossepowitch O, Dalbagni G. Transitional cell carcinoma
of the bladder in young adults: Presentation, natural history
and outcome. J Urol 2002;168(1):61-6.
https://pubmed.ncbi.nlm.nih.gov/12050493/
8) Ander H, Dönmez Mİ, Yitgin Y, Tefik T, Ziylan O, Oktar
T, et al. Urothelial carcinoma of the urinary bladder in
pediatric patients: A long-term follow-up. Int Urol Nephrol
2015;47(5):771-4.
https://doi.org/10.1007/s11255-015-0950-z
9) Berrettini A, Castagnetti M, Salerno A, Nappo SG,
Manzoni G, Rigamonti W, et al. Bladder urothelial
neoplasms in pediatric age: Experience at three tertiary
centers. J Pediatr Urol 2015;11(1):26.e1-5.
https://doi.org/10.1016/j.jpurol.2014.08.008
10) Wild PJ, Giedl J, Stoehr R, Junker K, Boehm S, van
Oers JM, et al. Genomic aberrations are rare in urothelial
neoplasms of patients 19 years or younger. J Pathol
2007;211(1):18-25.
https://doi.org/10.1002/path.2075
11) Migaldi M, Rossi G, Maiorana A, Sartori G, Ferrari P, De
Gaetani C, et al. Superficial papillary urothelial carcinomas
in young and elderly patients: A comparative study. BJU
Int 2004;94(3):311-6.
https://doi.org/10.1111/j.1464-410X.2004.04929.x
12) Mongiat-Artus P, Miquel C, van der Aa M, Buhard O,
Hamelin R, Bangma C, et al. Infrequent microsatellite
instability in urothelial cell carcinoma of the bladder in
young patients. Eur Urol 2006;49(4):685-90.
https://doi.org/10.1016/j.eururo.2005.11.024
13) Haecker FM, Bruder E. Bladder neoplasia in pediatric
patients-a single-center experience including a case series.
Children (Basel) 2023;10(10):1596.
https://doi.org/10.3390/children10101596
14) Baris D, Karagas MR, Verrill C, Johnson A, Andrew AS,
Marsit CJ, et al. A case-control study of smoking and
bladder cancer risk: Emergent patterns over time. J Natl
Cancer Inst 2009;101(22):1553-61.
https://doi.org/10.1093/jnci/djp361
15) Wilhelm-Benartzi CS, Christensen BC, Koestler
DC, Houseman EA, Schned AR, Karagas MR, et al.
Association of secondhand smoke exposures with DNA
methylation in bladder carcinomas. Cancer Causes Control
2011;22(8):1205-13.
https://doi.org/10.1007/s10552-011-9788-6
16) Selph S, Patnode C, Bailey SR, Pappas M, Stoner R,
Chou R. Primary care-relevant interventions for tobacco
and nicotine use prevention and cessation in children
and adolescents: Updated evidence report and systematic
review for the US preventive services task force. JAMA
2020;323(16):1599-1608.
https://doi.org/10.1001/jama.2020.3332
17) Mears A, Colemeadow J, Johal NS. Haematuria in
children. Br J Hosp Med (Lond) 2021;82(5):1-8.
https://doi.org/10.12968/hmed.2021.0046
18) Radmayr C, Bogaert G, Bujons A, Burgu B, Castagnetti
M, Hoen L, et al. European Association of Urology: EAU
guidelines on paediatric urology: update 2024.
19) Teoh JY, MacLennan S, Chan VW, Miki J, Lee HY, Chiong
E, et al. An international collaborative consensus statement
on en bloc resection of bladder tumour incorporating two
systematic reviews, a two-round delphi survey, and a
consensus meeting. Eur Urol 2020;78(4):546-69.
https://doi.org/10.1016/j.eururo.2020.04.059
20) Galiya R, Stanislav K, Jawdat J, Benjamin H, Boris C.
Pediatric urothelial bladder neoplasm. J Pediatr Urol
2022;18(6):833.e1-833.e4.
https://doi.org/10.1016/j.jpurol.2022.06.026
21) Lerena J, Krauel L, García-Aparicio L, Vallasciani S, Suñol
M, Rodó J. Transitional cell carcinoma of the bladder in
children and adolescents: Six-case series and review of the
literature. J Pediatr Urol 2010;6(5):481-5.
https://doi.org/10.1016/j.jpurol.2009.11.006
22) ElSharnoby O, Fraser N, Williams A, Scriven S, Shenoy
M. Bladder urothelial cell carcinoma as a rare cause of
haematuria in children: Our experience and review of
current literature. J Pediatr Surg 2022;57(7):1409-13.
https://doi.org/10.1016/j.jpedsurg.2021.09.007
23) Yafi FA, Brimo F, Steinberg J, Aprikian AG, Tanguay
S, Kassouf W. Prospective analysis of sensitivity and
specificity of urinary cytology and other urinary biomarkers
for bladder cancer. Urol Oncol 2015;33(2):66.e25-31.
https://doi.org/10.1016/j.urolonc.2014.06.008
24) Lobo J, Lobo C, Leça L, Rodrigues Â, Henrique R,
Monteiro P. Evaluation of the implementation and
diagnostic accuracy of the paris classification for
reporting urinary cytology in voided urine specimens:
A cyto-histological correlation study in a cancer center.
Pathobiology 2023;90(4):233-40.
https://doi.org/10.1159/000527980